Abstract:TNP-470, an analogue of a naturally secreted antibiotic of Aspergillus fumigatus fresenius - named fumagillin, has been shown to inhibit angiogenesis in vitro and in vivo. TNP-470 was one of the first antiangiogenic compounds to enter clinical trials for cancer, making it a valuable prototype for future trials of angiogenesis inhibitors in oncology. It was halted in clinical Phase II trials following its evaluation in Kaposi’s sarcoma, renal cell carcinoma, brain cancer, breast cancer, cervical cancer and prostate cancer. In early clinical reports, TNP-470 was tolerated up to 177 mg/m2 with neurotoxic effects being the principal dose limiting toxicity. To date, there are 500 papers published on TNP-470. They describe the antiangiogenic activity of TNP-470 including its anti-inflammatory, anti-infective and anti-obesity effects. Oxidative stress reduction and hyperpermeabilty decrease by TNP-470 account for yet another anti-cancer effect of this molecule. Mechanistic studies have identified cell cycle mediators and the protein methionine aminopeptidase-2 (MetAP-2) as molecular targets of TNP-470. Cell-cycle inhibition by TNP-470 is mediated at least in part by an activation of p21WAF1/CIP1 because of a p53-dependent mechanism, with reduction of the cyclin DCdk4 and cyclin E-Cdk 2 expression. Furthermore, it has been recently shown that FGFR1/PI3K/AKT signaling pathway is a novel target for the antiangiogenic effects of TNP-470. Coadministration of TNP-470 with chemotherapy increased drug delivery to the tumor followed by increased tumor response to cytotoxic therapy, implicating a potential role for these agents in combination treatment of solid tumors. Although TNP-470 is not approved for systemic use, this compound has one of the highest efficacies for the treatment of the broadest spectrum of tumor types. TNP-470 does exhibit side effects such as neurotoxicity that have deterred its acceptance as a viable treatment, but the current body of research on the synthesis of novel analogs and formulations of this molecule shows an exciting and promising “resurrection” of this drug as a potent antiangiogenic agent.

TNP-470: The Resurrection of the First Synthetic Angiogenesis Inhibitor

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

Anti-angiogenic Active Immunotherapy: a New Approach to Cancer Treatment

Inhibitory Effect of the Angiogenesis Inhibitor TNP-470 on Tumor Growth and Metastasis in Nude Mice Bearing Human Hepatocellular Carcinoma

A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis.

[Cancer therapy targeting tumor-induced neovascularization]

Experimental Study of the Effect of Angiogenesis Inhibitor TNP-470 on the Growth and Metastasis of Gastric Cancer in Vivo

Anti-tumor Effect of Angiogenesis Inhibitor TNP-470 on the Human Nasopharyngeal Carcinoma Cell Line NPC/HK1.

Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells

A Novel Antitumor Protein from the Mushroom Pholiota Nameko Induces Apoptosis of Human Breast Adenocarcinoma MCF-7 Cells in Vivo and Modulates Cytokine Secretion in Mice Bearing MCF-7 Xenografts.

Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles

Therapeutic Targeting of Angiogenesis with a Recombinant CTT Peptide–Endostatin Mimic–Kringle 5 Protein

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer

Mechanism and rational combinations with GP-2250, a novel oxathiazine derivative, in ovarian cancer

Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth

Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.

Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice

Curcumin Analog, GO-Y078, Overcomes Resistance to Tumor Angiogenesis Inhibitors

Combination of Angiogenesis Inhibitor TNP-470 with Cytotoxic Drugs in Experimental Therapy of Nasopharyngeal Carcinoma.

Discovery of a Dual Tubulin and Neuropilin-1 (NRP1) Inhibitor with Potent in Vivo Anti-Tumor Activity Via Pharmacophore-based Docking Screening, Structure Optimization, and Biological Evaluation.